Company: NIVFW
Filing Date: 2025-03-07
Form Type: F-1
Source: 0001213900-25-021404
Chunk: 131

Company: NewGenIvf Group Ltd
Filing Date: 2025-03-07
Form: F-1
Chunk 131
---
 sole discretion of White Lion, to 9.99%) of the number of Class A Ordinary Shares outstanding immediately prior to the issuance of Class A Ordinary Shares issuable pursuant to a purchase notice. The Company has the right to terminate the White Lion Purchase Agreement in the event of a material breach of the White Lion Purchase Agreement by White Lion. The White Lion Purchase Agreement also automatically terminates upon the earlier of (i) the end of the Commitment Period and (ii) the date that the Company commences a voluntary bankruptcy proceeding, a custodian is appointed for the Company or for all or substantially all of its property, or the Company makes a general assignment for the benefit of its creditors. In consideration for the commitments of White Lion, as described above, the Company has agreed that it will issue to White Lion 700,000 Class A Ordinary Shares (“Commitment Shares”). Additional Ordinary Shares may be issued to White Lion under certain conditions, including in connection with material transactions or upon achieving specified investment thresholds. The Commitment Shares will be fully earned by White Lion regardless of termination of the White Lion Purchase Agreement. 92 The White Lion Purchase Agreement and the RRA contain customary representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties. Business Model With a focus on providing fertility treatments to fulfil couples and individuals’ dreams of raising children, NewGenIvf offers mainly two services, namely: (i) IVF treatment service, comprising traditional IVF and egg donation; and (ii) surrogacy and ancillary caring services. The following table sets forth NewGenIvf’s revenue by service offerings and as a percentage of total revenue for the periods indicated:

|                               |     | For                         
 the Year ended December 31, |      2023 |     |   |       |     |     |      2022 |     |   |       |
|:------------------------------|:----|:----------------------------|----------:|:----|:--|------:|:----|:----|----------:|:----|:--|------:|
|                               |     | US$                         |           |     | % |       |     | US$ |           |     | % |       |
| IVF Treatment Service         |     |                             | 4,021,696